Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Autologous CD30 CAR T Cell(New York Medical College) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Autologous CD30 CAR T Cell(New York Medical College): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals,
9 min read
Regulatory T Cell Therapy(Medical University of Vienna) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Regulatory T Cell Therapy(Medical University of Vienna): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deal
9 min read
SRD-003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
SRD-003: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
YL-205 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
YL-205: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BBM-A101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
BBM-A101: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
EB-NK-FM Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
EB-NK-FM: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KSQ-004EX Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
KSQ-004EX: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ACR-2316 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ACR-2316: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy(Chinese PLA General Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy(Chinese PLA General Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
Red cell units that are genotype matched at the RHD and RHCE loci(Children's Hospital of Philadelphia) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Red cell units that are genotype matched at the RHD and RHCE loci(Children's Hospital of Philadelphia): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
Adipose-derived multipotent mesenchymal stem cells(Guangdong Hospital of Traditional Chinese Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Adipose-derived multipotent mesenchymal stem cells(Guangdong Hospital of Traditional Chinese Medicine): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
Super Hi-TCR-T Cells Targeting Nectin4/NKG2DL/TROP2/B7H3/GPC3/FAP(Eastern Hepatobiliary Surgery Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Super Hi-TCR-T Cells Targeting Nectin4/NKG2DL/TROP2/B7H3/GPC3/FAP(Eastern Hepatobiliary Surgery Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence revi